NRX Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, revealing a net patient service revenue of approximately $1.1 million, a significant increase from zero revenue in the same period last year. This revenue was generated following the acquisition of Dura Medical, LLC, which was completed on September 8, 2025. The company incurred a net loss of $1.4 million for the quarter, a notable improvement compared to a net loss of $5.5 million in the first quarter of 2025. The loss per share for the quarter was $0.04, compared to $0.34 in the prior year.
Total operating expenses for the first quarter of 2026 were approximately $5.8 million, up from $3.8 million in the same quarter of 2025. The increase in expenses was primarily driven by the cost of patient services, which amounted to $0.6 million, and a rise in research and development expenses to $1.3 million, reflecting the company's ongoing investment in clinical trials and product development. General and administrative expenses also rose to $3.8 million, attributed to increased employee costs and office expenses.
In terms of operational developments, NRX Pharmaceuticals has expanded its clinical services through its subsidiary HOPE Therapeutics, which now operates five locations in Florida and plans to expand further. The company has also initiated several strategic initiatives, including the formation of two new subsidiaries, NRx Defense Systems, Inc. and GeNeuro, Inc., aimed at advancing clinical findings related to mental health treatments. The acquisition of Dura is expected to enhance the company's service offerings and revenue generation capabilities.
Looking ahead, NRX Pharmaceuticals anticipates continued operating losses as it integrates Dura and pursues additional acquisitions. The company has secured sufficient operating capital to fund its drug development operations through at least the third quarter of 2026. Management is optimistic about future revenue growth from clinical operations and potential pharmaceutical product sales, contingent upon successful FDA approvals for its lead drug candidates, NRX-100 and NRX-101. However, the company has acknowledged substantial doubt regarding its ability to continue as a going concern for the next twelve months, emphasizing the need for additional financing to support its operations and growth initiatives.
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders such as suicidal depression, bipolar disorder, PTSD, and chronic pain. Its key products include NMDA receptor modulators like NRX-100 and NRX-101, targeting rapid relief of suicidality and depression. The company also operates HOPE Therapeutics, a care delivery platform with clinics treating psychiatric conditions, integrating innovative drug development with patient care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.